.jpg)
.png)
All
Clinical Case The patient is a 67-year-old white gentleman with type 2 diabetes mellitus (T2DM), hypertension (HTN), 20-pack-year smoking history, and dyslipidemia. He presented to the Lipidology Clinic for a follow-up of his diabetes and atherogenic dyslipidemia. He has never experienced any... more
The new ICD-10 Codes released by the Center for Medicare & Medicaid Services (CMS) are now in effect. The codes became effective October 1, 2016. The two new specific codes for FH are: E78.01: Familial hypercholesterolemia Z83.42: Family history of familial... more
Over the course of my 36-year career, the practice of medicine has changed dramatically. When I was an intern at Georgetown University Hospital, we treated heart attacks with oxygen, morphine, and sometimes not much more than prayers. Barely anyone at that time could conceive of doing a cardiac... more
Statin-associated muscle symptoms (SAMS) are the most common form of statin intolerance and are associated with increased risk of cardiovascular events that manifest from statin underutilization and discontinuation. Treatment to reduce low-density lipoprotein cholesterol (LDL-C) and other... more
The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial was a randomized trial in 27,564 patients with stable atherosclerotic cardiovascular disease (ASCVD), evaluating evolocumab vs placebo added to statin therapy.(1) The hazard ratio for... more
December 18, 2018 Melissa Goetz Lindsey Sutton Co-Presidents Familial Chylomicronemia Syndrome Foundation 7523 Rowena St San Diego, CA 92119 An Open Letter to Familial Chylomicronemia Syndrome... more
The National Lipid Association (NLA) endorses the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, published by the American College of Cardiology on April 1 in the... more